LA JOLLA, Calif., September 11, 2009 — Dieter Wolf, M.D., and colleagues at Burnham Institute for Medical Research (Burnham) have illuminated how competition between proteins enhances combinatorial diversity during ubiquitination (the process that marks proteins for destruction). Using S. pombe fission yeast as a model, the Wolf laboratory uncovered an intricate relationship, in which an array of Fbox proteins alternately attach to and are kicked off of a cullin-RING ubiquitin ligase (CRL1) containing CUL1 and Skp1. Without the Fbox, CRL1 cannot attach to the protein substrate or recruit ubiquitin, potentially preserving aberrant proteins. The research was published in the journal Molecular Cell on September 11.
S. pombe expresses 16 different Fbox proteins, some of which are regulated by the COP9 signalosome (CSN). The study shows that these proteins attach to CRL1 but are kicked off by the competing protein CAND1. Fbox proteins and CAND1 continue to trade places until they come in contact with the appropriate substrate of the protein being degraded. This phosphorylated substrate recruits the protein N8, which attaches to the complex and stabilizes the Fbox protein. Then the complex can attach to the substrate and recruit ubiquitin. Once this process is completed, N8 is removed, Fbox is destabilized and the process begins again.
“The tension between CAND1 and Fbox gives more Fbox proteins the opportunity to attach to CRL1,” says Dr. Wolf. “Without CAND1, more prevalent Fbox proteins would dominate the process. We also found that, to bind to CRL1, the Fbox proteins must contain a specific proline residue. Only when the substrate is present can the Fbox protein be stabilized in the complex.”
The laboratory tested eight of the 16 Fbox proteins. They found that five of the eight were regulated by the CSN and that CSN-insensitive proteins were missing a proline residue. They also found that the proline residue was required for CRL1 complex formation. The laboratory also determined that CAND1 deficiency and CSN deficiency produced different phenotypes, outlining the different roles they play in stabilizing CRL1.
About Burnham Institute for Medical Research
Burnham Institute for Medical Research is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The institute ranks among the top four institutions nationally for NIH grant funding and among the top 25 organizations worldwide for its research impact. For the past decade (1999-2009), Burnham ranked first worldwide in the fields of biology and biochemistry for the impact of its research publications (defined by citations per publication), according to the Institute for Scientific Information.
Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit public benefit corporation. For more information, please visit www.burnham.org.